Ticker Details
Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).
IPO Date:	February 6, 2007
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$9.88B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.88 | 2.55%
Avg Daily Range (30 D):	$9.01 | 1.86%
Avg Daily Range (90 D):	$9.61 | 1.91%

Institutional Daily Volume
Avg Daily Volume:	.22M
Avg Daily Volume (30 D):	.31M
Avg Daily Volume (90 D):	.28M

Trade Size
Avg Trade Size (Sh.):	42
Avg Trade Size (Sh.) (30 D):	23
Avg Trade Size (Sh.) (90 D):	23

Institutional Trades
Total Institutional Trades:	2,492
Avg Institutional Trade:	$6.92M
Avg Institutional Trade (30 D):	$20.31M
Avg Institutional Trade (90 D):	$19.23M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$7.42M
Avg Closing Trade (30 D):	$19.26M
Avg Closing Trade (90 D):	$22.15M
Avg Closing Volume:	33.31K

News

Feb 11, 2026 @ 10:00 AM Madrigal Expands its MASH Pipeline with Exclusive ... Source: Na

Jan 11, 2026 @ 5:01 PM Roblox, First Solar, And League Enterprise Are Amo... Source: Nabaparna Bhattacharya

Jan 9, 2026 @ 1:00 PM Madrigal Expands its MASH Pipeline with Exclusive ... Source: Na

Jan 2, 2026 @ 6:29 PM Gene Therapy: 5 Biotech Stocks Chasing the $36B Pr... Source: Prnewswire

Dec 14, 2025 @ 2:30 PM 2 Predictions for Novo Nordisk in 2026 Source: Prosper Junior Bakiny

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-12.85	$-2.53	$-12.85
Diluted EPS	$-12.85	$-2.53	$-12.85
Revenue	$958.4M	$321.08M	$958.4M
Gross Profit
Net Income / Loss	$-288.28M	$-58.58M	$-288.28M
Operating Income / Loss	$-300.1M	$-59.61M	$-300.1M
Cost of Revenue
Net Cash Flow	$98.75M	$-96.92M	$98.75M
PE Ratio

Splits
Jul 25, 2016	1:35